Novel Technologies in Diabetes Mellitus Therapy

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: closed (15 August 2022) | Viewed by 5233

Special Issue Editor


E-Mail Website
Guest Editor
Department of Internal Medicine and Medical Specialties, University of Genova, 16132 Genova, Italy
Interests: the role of caveoles in the insulin and IGF1 signal; new technologies in the treatment of diabetes mellitus; role of bariatric surgery in the regulation of metabolism
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The first use of insulin on 11 January 1921 completely changed the life expectancy of patients with Type 1 Diabetes, which has since become a chronic disease. For many years, however, insulin therapy has been based essentially on clinical criteria. In fact, measuring glycemia was difficult and impossible to do at home. In the 1930s and 1940s, glycosuria became the main index to manage insulin therapy. The use of portable glucometers made the self-monitoring of blood glucose the standard of care, which improved patient quality of life. Now, the use of sensors to determine interstitial glucose represents the last frontier. Along with the development of systems for determining blood glucose, there has been also a notable advance in insulin delivery devices from syringes to pens and insulin pumps.

In 2020, for the first time, the ADA standard of diabetes care included the chapter “Diabetes and Technology.” In the last 20 years, there have been great advances in this field. On the one hand, the number, reliability, and spread of sensors to measure interstitial glycemia greatly increased. On the other hand, the insulin pump evolved toward the closed loop hybrid system. Finally, the high connectivity between the players implied in diabetes management (patients, caregivers, medical and nursing staff) have further expanded and complicated disease management. In this Special Issue of Life, all these aspects will be addressed.

Dr. Davide Maggi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetes mellitus therapy
  • diabetes and technology
  • diabetes and COVID‐19
  • diabetes management
  • measurement of glycemia
  • islets of Langerhans
  • insulin delivery

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

25 pages, 1228 KiB  
Review
Automated Insulin Delivery (AID) Systems: Use and Efficacy in Children and Adults with Type 1 Diabetes and Other Forms of Diabetes in Europe in Early 2023
by Marta Bassi, Daniele Franzone, Francesca Dufour, Marina Francesca Strati, Marta Scalas, Giacomo Tantari, Concetta Aloi, Alessandro Salina, Giuseppe d’Annunzio, Mohamad Maghnie and Nicola Minuto
Life 2023, 13(3), 783; https://doi.org/10.3390/life13030783 - 14 Mar 2023
Cited by 2 | Viewed by 4975
Abstract
Type 1 diabetes (T1D) patients’ lifestyle and prognosis has remarkably changed over the years, especially after the introduction of insulin pumps, in particular advanced hybrid closed loop systems (AHCL). Emerging data in literature continuously confirm the improvement of glycemic control thanks to the [...] Read more.
Type 1 diabetes (T1D) patients’ lifestyle and prognosis has remarkably changed over the years, especially after the introduction of insulin pumps, in particular advanced hybrid closed loop systems (AHCL). Emerging data in literature continuously confirm the improvement of glycemic control thanks to the technological evolution taking place in this disease. As stated in previous literature, T1D patients are seen to be more satisfied thanks to the use of these devices that ameliorate not only their health but their daily life routine as well. Limited findings regarding the use of new devices in different age groups and types of patients is their major limit. This review aims to highlight the main characteristics of each Automated Insulin Delivery (AID) system available for patients affected by Type 1 Diabetes Mellitus. Our main goal was to particularly focus on these systems’ efficacy and use in different age groups and populations (i.e., children, pregnant women). Recent studies are emerging that demonstrate their efficacy and safety in younger patients and other forms of diabetes. Full article
(This article belongs to the Special Issue Novel Technologies in Diabetes Mellitus Therapy)
Show Figures

Figure 1

Back to TopTop